Salinomycin, traditionally used as an anti-coccidial drug, has recently been shown to possess anti-cancer and
anti-cancer stem cell (CSC) effects, as well as activities to overcome multi-drug resistance based on studies using human
cancer cell lines, xenograft mice, and in case reports involving cancer patients in pilot clinical trials. Therefore, salinomycin
may be considered as a promising novel anti-cancer agent despite its largely unknown mechanism of action.
This review summarizes the pharmacologic effects of salinomycin and presents possible mechanisms by which salinomycin
exerts its anti-tumorigenic activities. Recent advances and potential complications that might limit the utilization of salinomycin
as an anti-cancer and anti-CSC agent are also presented and discussed.